KRAS and colorectal carcinoma: EGFR–RAS signaling is activated in 3D bioprinted cells as well (Figure 2, Supplementary Figure S3 and Supplementary Table S2), and this pathway is perhaps the most commonly dysregulated one in CRC, with ∼40% of patients presenting with KRAS mutations (and up to 10% having NRAS or BRAF mutations) (Inamura, 2018).